• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

CytomX Therapeutics (CTMX)

Common Shares
Sell: $5.32|Buy: $5.45|Change: 0.14 (2.66%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designedto take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Address

151 Oyster Point Boulevard
Suite 400
South San Francisco
CA
USA
94080

Telephone

+1 650 5153185

Website

https://www.cytomx.com

Sector 

Healthcare

Forecast key dates

NameKey Date
CytomX Therapeutics Inc Third Quarter Earnings Conference Call for 20262026-11-06T17:00:00
CytomX Therapeutics Inc Third Quarter Earnings Results for 20262026-11-06T00:00:00
CytomX Therapeutics Inc Second Quarter Earnings Conference Call for 20262026-08-07T17:00:00
CytomX Therapeutics Inc Second Quarter Earnings Results for 20262026-08-07T00:00:00
CytomX Therapeutics Inc Annual General Meeting for 20262026-06-11T13:30:00
CytomX Therapeutics Inc First Quarter Earnings Conference Call for 20262026-05-12T08:00:00
CytomX Therapeutics Inc First Quarter Earnings Results for 20262026-05-12T00:00:00
CytomX Therapeutics Inc Fourth Quarter Earnings Conference Call for 20252026-03-06T17:00:00
CytomX Therapeutics Inc Fourth Quarter Earnings Results for 20252026-03-06T00:00:00
CytomX Therapeutics Inc Annual Report for 20252026-03-06T00:00:00

Previous key dates

NameKey Date
Piper Sandler 37(th) Annual Healthcare Conference2025-12-04T13:00:00
8(th) Annual Evercore Healthcare Conference2025-12-02T13:45:00
Jefferies Global Healthcare Conference2025-11-20T04:00:00
CytomX Therapeutics Inc Third Quarter Earnings Conference Call for 20252025-11-06T17:00:00
CytomX Therapeutics Inc Third Quarter Earnings Results for 20252025-11-06T00:00:00
Morgan Stanley 23rd Annual Global Healthcare Conference 20252025-09-10T13:05:00
H.C. Wainwright 27th Annual Global Investment Conference2025-09-09T11:30:00
Cantor Global Healthcare Conference 20252025-09-04T08:35:00
CytomX Therapeutics Inc Second Quarter Earnings Conference Call for 20252025-08-07T17:00:00
CytomX Therapeutics Inc Second Quarter Earnings Result for 20252025-08-07T00:00:00
CytomX Therapeutics Inc Annual General Meeting for 20252025-06-11T13:30:00
Jefferies Global Healthcare Conference2025-06-05T14:35:00
CytomX Therapeutics Inc First Quarter Earnings Conference Call for 20252025-05-12T08:00:00
CytomX Therapeutics Inc First Quarter Earnings Result for 20252025-05-12T00:00:00
Barclays 27th Annual Global Healthcare Conference2025-03-12T15:00:00
CytomX Therapeutics Inc Fourth Quarter Earnings Conference Call for 20242025-03-06T17:00:00
CytomX Therapeutics Inc Fourth Quarter Earnings Result for 20242025-03-06T00:00:00
CytomX Therapeutics Inc Annual Report for 20242025-03-06T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.